NDA 018132 · Hospira
Dopamine Hydrochloride
Dopamine Hydrochloride · Injection
Last checked: Nov 20, 2026Latest source record: Sep 12, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1981
May 19, 1981
Approved uses
1
Original approval plus efficacy supplements
Registered trials
586
103 Phase 3, 70 recruiting
FAERS reports
725
694 serious, 313 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 28, 2026.
Dopamine HCl Injection is indicated to improve hemodynamic status in patients in distributive shock or shock due to reduced cardiac output. Dopamine HCl Injection is a catecholamine indicated to improve hemodynamic status in patients in shock. (1)
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 19, 1981 Original approval
4 products under this application
- DOPAMINE HYDROCHLORIDE · DOPAMINE HYDROCHLORIDE 80MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
- DOPAMINE HYDROCHLORIDE · DOPAMINE HYDROCHLORIDE 80MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- DOPAMINE HYDROCHLORIDE · DOPAMINE HYDROCHLORIDE 160MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- DOPAMINE HYDROCHLORIDE · DOPAMINE HYDROCHLORIDE 40MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Dopamine" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Diagnosis of PheochromocytomaRecruiting
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00004847 · 3,000 participants (planned) · Start Mar 22, 2000 · Primary completion Nov 30, 2048
Drug: ([18F]-DOPA); ([18F]-6F-DA) · For: Pheochromocytoma; Endocrine Disease; Endocrine Diseases
Sites: Bethesda, Maryland
- Target Hemodynamics and Brain Injury During General Anesthesia in the ElderlyPivotal-lookingSuspended
Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoAcademic, hospital or other
NCT02428062 · 1,812 participants (planned) · Start Oct 2014 · Primary completion Dec 2018
Drug: Phenylephrine; Intravenous fluids and 4 more · For: Post-operative Cognitive Dysfunction
Sites: Milan, Italy
- Dopamine and Norepinephrine in Shock PatientsPivotal-lookingCompleted
Sepsis Occurrence in Acutely Ill PatientsAcademic, hospital or other
NCT00314704 · 1,679 participants · Start Dec 2003 · Primary completion Oct 2007
Drug: dopamine versus norepinephrine · For: Shock
Sites: Vienna, Austria; Brussels, Belgium; Charleroi, Belgium · 8 sites in all
- Platform Adaptive Embedded Trial for Acute Respiratory Distress SyndromePivotal-lookingStatus unknown
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT05658692 · 1,000 participants (planned) · Start Oct 1, 2022 · Primary completion Oct 2023
Drug: glucocorticoid therapy; Thymosin Alpha and 5 more · For: Acute Respiratory Distress Syndrome
Sites: Beijing, China; Chengdu, China; Guangdong, China · 11 sites in all
Ken Marek, MDAcademic, hospital or other
NCT01141023 · 952 participants · Start Jun 2010 · Primary completion Jun 30, 2020
Drug: DaTscan · For: Parkinson Disease
Sites: Birmingham, Alabama; Sun City, Arizona; La Jolla, California · 34 sites in all
- PRolaCT - Three Prolactinoma RCTsPivotal-lookingStatus unknown
Leiden University Medical CenterAcademic, hospital or other
NCT04107480 · 880 participants (planned) · Start Jun 21, 2019 · Primary completion Mar 31, 2024
Drug: Dopamine Agonists · For: Prolactinoma; Prolactin-Producing Pituitary Tumor
Sites: Amsterdam-Zuidoost, Netherlands; Delft, Netherlands; Leiden, Netherlands
- Open-Label Safety Study of AXS-05 in Subjects With DepressionPivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT04039022 · 876 participants · Start Jul 8, 2019 · Primary completion Oct 23, 2020
Drug: AXS-05 (dextromethorphan and bupropion) oral tablets · For: Major Depressive Disorder; Treatment Resistant Depression; Depression
Sites: Phoenix, Arizona; Little Rock, Arkansas; Bellflower, California · 51 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective47
- hypotension46
- platelet count decreased46
- pneumonia46
- pyrexia41
- renal impairment41
- sepsis37
- blood pressure decreased35
- cardiac failure35
- condition aggravated35
- renal failure34
- anaemia33
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 54 |
| 2005 | 9 |
| 2006 | 12 |
| 2007 | 22 |
| 2008 | 38 |
| 2009 | 32 |
| 2010 | 42 |
| 2011 | 45 |
| 2012 | 39 |
| 2013 | 38 |
| 2014 | 18 |
| 2015 | 28 |
| 2016 | 31 |
| 2017 | 25 |
| 2018 | 25 |
| 2019 | 34 |
| 2020 | 25 |
| 2021 | 48 |
| 2022 | 45 |
| 2023 | 31 |
| 2024 | 37 |
| 2025 | 30 |
| 2026 | 14 |
Recalls
1 FDA enforcement reports for this application.
Sep 4, 2026 · Class II · Ongoing
Lack of Assurance of Sterility
Shortages
FDA's drug shortage list.
Current · updated Nov 9, 2026
Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01). Other
Current · updated Nov 9, 2026
Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20). Other
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antipsychotic Drugs and Cognitive Function: A Systematic Review and Network Meta-Analysis.
Feber L, Peter NL, Chiocchia V, et al. · JAMA Psychiatry 2025 · Systematic Review, Network Meta-Analysis
- Comparison of dopamine and norepinephrine in the treatment of shock.
De Backer D, Biston P, Devriendt J, et al. · N Engl J Med 2010 · Comparative Study, Multicenter Study
- Cortisol decreases and serotonin and dopamine increase following massage therapy.
Field T, Hernandez-Reif M, Diego M, et al. · Int J Neurosci 2005 · Clinical Trial, Randomized Controlled Trial
- Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases.
Schneider-Thoma J, Zhu Y, Qin M, et al. · Lancet 2026 · Comparative Study, Network Meta-Analysis
- THE EFFICACY AND SAFETY OF VASOPRESSORS FOR SEPTIC SHOCK PATIENTS: A SYSTEMIC REVIEW AND NETWORK META-ANALYSIS.
Jia L, Wang P, Li C, et al. · Shock 2023 · Systematic Review, Network Meta-Analysis
- Cortical dopamine reduces the impact of motivational biases governing automated behaviour.
Scholz V, Hook RW, Kandroodi MR, et al. · Neuropsychopharmacology 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.